Ralf Gold

47.3k total citations · 6 hit papers
780 papers, 28.2k citations indexed

About

Ralf Gold is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Ralf Gold has authored 780 papers receiving a total of 28.2k indexed citations (citations by other indexed papers that have themselves been cited), including 324 papers in Pathology and Forensic Medicine, 278 papers in Neurology and 165 papers in Immunology. Recurrent topics in Ralf Gold's work include Multiple Sclerosis Research Studies (314 papers), Peripheral Neuropathies and Disorders (174 papers) and Polyomavirus and related diseases (95 papers). Ralf Gold is often cited by papers focused on Multiple Sclerosis Research Studies (314 papers), Peripheral Neuropathies and Disorders (174 papers) and Polyomavirus and related diseases (95 papers). Ralf Gold collaborates with scholars based in Germany, United States and Switzerland. Ralf Gold's co-authors include Ralf A. Linker, Klaus V. Toyka, Aiden Haghikia, Hans‐Peter Hartung, Kerstin Hellwig, Klaus V. Toyka, Andrew Chan, Ludwig Kappos, Hans Lassmann and Kalliopi Pitarokoili and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Ralf Gold

748 papers receiving 27.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 1.3k citations Ralf Gold, Ludwig Kappos et al. profile →
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

2011 892 citations Ralf A. Linker, Ralf Gold et al. profile →
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution

2019 861 citations Ralf Gold et al. profile →
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

1994 623 citations Ralf Gold et al. profile →
Sex and gender issues in multiple sclerosis

2013 391 citations Ralf Gold et al. Therapeutic Advances in Neurological Disorders profile →
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

2019 308 citations Simon Faissner, Ralf Gold et al. profile →

Peers

Countries citing papers authored by Ralf Gold

Since Specialization

Citations

This map shows the geographic impact of Ralf Gold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Gold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Gold more than expected).

Fields of papers citing papers by Ralf Gold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf Gold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Gold. The network helps show where Ralf Gold may publish in the future.

Co-authorship network of co-authors of Ralf Gold

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Gold. A scholar is included among the top collaborators of Ralf Gold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Gold. Ralf Gold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis 2025 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Athina‐Maria Aloizou, Christoph H. Lohmann, Simon Faissner, (unknown), Dominic Borie, Thomas Mika, Roland Schroers, Jeremias Motte, Ralf Gold	1
2	Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy 2024 ·European Journal of Neurology ·Anna Lena Fisse, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Grüter, (unknown), Christiane Schneider‐Gold, Ralf Gold, (unknown), Kalliopi Pitarokoili, Jeremias Motte, Larissa Arning	2
3	Large-fiber neuropathy in Parkinson’s disease: a narrative review 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Ralf Gold, Kalliopi Pitarokoili, Lars Tönges	1
4	Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy 2024 ·Journal of Neurology ·(unknown), Dietrich Sturm, (unknown), Nataly Stylianou, (unknown), (unknown), Thomas Grüter, Jörg Philipps, (unknown), Christoph Maier, (unknown), Elena Enax‐Krumova, Matthias Vorgerd, Peter Schwenkreis, Ralf Gold, Anna Lena Fisse, Jeremias Motte, Kalliopi Pitarokoili	0
5	Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease 2024 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), Carolin Schwake, Ingo Kleiter, Bianca Teegen, (unknown), Christian Prehn, (unknown), Marius Ringelstein, Orhan Aktaş, Refik Pul, (unknown), Carsten Lukas, Iris‐Katharina Penner, Ralf Gold, Ruth Schneider, (unknown)	2
6	Clinical and device-based predictors of improved experience of activities of daily living after a multidisciplinary inpatient treatment for people with Parkinson’s disease: a cohort study 2024 ·Therapeutic Advances in Neurological Disorders ·(unknown), (unknown), Julius Welzel, Johanna Geritz, Clint Hansen, Ralf Gold, Walter Maetzler, (unknown), Lars Tönges	3
7	The association of vagal atrophy with parameters of autonomic function in multiple system atrophy and progressive supranuclear palsy 2024 ·Therapeutic Advances in Neurological Disorders ·(unknown), (unknown), (unknown), (unknown), Eva Kühn, (unknown), (unknown), (unknown), (unknown), Katharina Müller, Jeremias Motte, (unknown), Christiane Schneider‐Gold, Ralf Gold, (unknown), Lars Tönges, Kalliopi Pitarokoili	0
8	Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments 2022 ·CNS Drugs ·Simon Faissner, Ralf Gold	21
9	COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany 2022 ·SHILAP Revista de lepidopterología ·(unknown), Dirk Bartig, Daniel Richter, (unknown), Siegfried Muhlack, Ralf Gold, Christos Krogias, Lars Tönges	1
10	Hypoechogenicity of brainstem raphe in long-COVID syndrome–less common but independently associated with depressive symptoms: a cross-sectional study 2022 ·Journal of Neurology ·Daniel Richter, (unknown), (unknown), (unknown), (unknown), Ralf Gold, Christos Krogias, Simon Faissner	8
11	Vagal cross-sectional area correlates with parasympathetic dysfunction in Parkinson's disease 2022 ·Brain Communications ·(unknown), Katharina Mueller, (unknown), Eva Kühn, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Grüter, Anna Lena Fisse, Jeremias Motte, Min‐Suk Yoon, Ralf Gold, Christiane Schneider‐Gold, Lars Tönges, Kalliopi Pitarokoili	14
12	Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study 2021 ·Brain Sciences ·(unknown), Eva Kühn, (unknown), (unknown), (unknown), (unknown), Katharina Müller, (unknown), Christiane Schneider‐Gold, Ralf Gold, Kalliopi Pitarokoili, Lars Tönges, (unknown)	8
13	Correlates of polyneuropathy in Parkinson’s disease 2020 ·Annals of Clinical and Translational Neurology ·Eva Kühn, (unknown), (unknown), Katharina Müller, (unknown), (unknown), Jeremias Motte, Anna Lena Fisse, Christiane Schneider‐Gold, Ralf Gold, Kalliopi Pitarokoili, Lars Tönges	9
14	Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology 2019 ·Cells ·Daniel Richter, Aristeidis H. Katsanos, Christoph Schroeder, Georgios Tsivgoulis, George P. Paraskevas, Thomas Müller, Andrei V. Alexandrov, Ralf Gold, Lars Tönges, Christos Krogias	27
15	Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease 2019 ·Cells ·(unknown), (unknown), (unknown), Fabian Maass, Siegfried Muhlack, Ralf Gold, Aiden Haghikia, Lars Tönges	31
16	Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa–carbidopa intestinal gel, and deep brain stimulation 2019 ·Journal of Neural Transmission ·Daniel Richter, Dirk Bartig, Wolfgang H. Jost, (unknown), Britta Stumpe, Ralf Gold, Christos Krogias, Lars Tönges	11
17	Testosterone Differentially Affects T Cells and Neurons in Murine and Human Models of Neuroinflammation and Neurodegeneration 2017 ·American Journal Of Pathology ·Megan G. Massa, Christina David, Stefanie Jörg, Johannes Berg, Barbara Gisevius, Sarah Hirschberg, Ralf A. Linker, Ralf Gold, Aiden Haghikia	32
18	Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study 2012 ·Journal of Neurology ·Ludwig Kappos, G. Comi, Jackie Palace, Arno Siever, Maria Giovanna Marrosu, Matthias Mehling, Rebecca Gottschalk, (unknown), Anthony D. Keil, Davorka Tomic, Philipp von Rosenstiel, Ralf Gold	4
19	Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study 2006 ·UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, (unknown), (unknown), Klaus Schmierer, Tarek Yousry, Meixiao Long, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, (unknown)	13
20	BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis 2006 ·UCL Discovery (University College London) ·Ludwig Kappos, D. H. Miller, David MacManus, Ralf Gold, Eva Havrdová, (unknown), CH Polman, Klaus Schmierer, (unknown), Min Yang, Mefkûre Eraksoy, Eva Meluzínová, Ivan Rektor, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact